SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in Mexico to Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health regulatory authority for Mexico, for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients, "Inmunoensayo de flujo lateral para la detección cualitativa de la proteína nucleocápside del SARS-CoV-2".
Related Post
- Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel - January 19th, 2021
- Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience - January 19th, 2021
- Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - January 19th, 2021
- NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member - January 19th, 2021
- Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - January 19th, 2021
- Bespoke Extracts Increases Conversion Price of Outstanding Discount Convertible Debentures - January 19th, 2021
- Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant - January 19th, 2021
- Novan Provides Enrollment Update and Announces New Corporate Headquarters - January 19th, 2021
- Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer - January 19th, 2021
- Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters - January 19th, 2021
- Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option - January 19th, 2021
- VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) - January 19th, 2021
- Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference - January 19th, 2021
- Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer - January 19th, 2021
- Agenus to Participate in B. Riley Securities' Oncology Investor Conference - January 19th, 2021
- Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. - January 19th, 2021
- Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration - January 19th, 2021
- Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021 - January 19th, 2021
- Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference - January 19th, 2021
- Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein - January 19th, 2021
- Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure - January 17th, 2021
- Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update - January 17th, 2021
- SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones - January 17th, 2021
- PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology - January 17th, 2021
- Grey Cloak Tech Fuel4Thought™ Migraine Formula Results Published in World Journal of Advanced Research and Reviews - January 17th, 2021
- One World Pharma Receives Colombian Approval for Five THC Strains - January 17th, 2021
- Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in... - January 17th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - January 17th, 2021
- Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference - January 17th, 2021
- Ceapro Inc. to Present at NobleCon17 - January 17th, 2021
- Tauriga Sciences Inc. Completes Payment for the Entirety of its Initial Production Run of its Caffeine Infused Version of Tauri-Gum - January 17th, 2021
- DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years - January 17th, 2021
- Dr. Han Myint Appointed as NextCure’s Chief Medical Officer - January 17th, 2021
- AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET - January 17th, 2021
- Global WholeHealth Partners, Corp (GWHP: OTC) Announces the Beginning Research for Saliva COVID 19 SARS 2 Antigen (N+S) Tests - January 17th, 2021
- Qilian International Holding Group Limited Announces Closing of Initial Public Offering - January 17th, 2021
- ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - January 17th, 2021
- Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant... - January 17th, 2021
- TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference - January 16th, 2021
- Manager’s transactions - January 16th, 2021
- VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC - January 16th, 2021
- MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors - January 16th, 2021
- Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital - January 16th, 2021
- Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration - January 16th, 2021
- Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer - January 16th, 2021
- Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17... - January 16th, 2021
- BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS)... - January 16th, 2021
- Golden Leaf Holdings Announces Oversubscribed Private Placement and increase in offering size - January 16th, 2021
- Aeterna Zentaris to Present at NobleCon17 - January 16th, 2021
- Tauriga Sciences Inc. Taking Immediate Steps to Strengthen its Board of Directors and Corporate Governance Protocols With Aim Towards Future Up-List... - January 16th, 2021
- Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update - January 16th, 2021
- Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - January 16th, 2021
- Tower One Provides Construction and Business Update for the Month of December 2020 - January 16th, 2021
- Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility Terms - January 16th, 2021
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux - January 16th, 2021
- Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th - January 16th, 2021
- Muama Ryoko Reviews - Best 4G Wifi Router? - Product Review by Mike Vaughn - January 16th, 2021
- Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast - January 16th, 2021
- Immune Therapeutics Inc. Spinoff Cytocom, Inc. to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week... - January 12th, 2021
- Tiziana Life Sciences to Present at Biotech Showcase Digital 2021 - January 12th, 2021
- Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee - January 12th, 2021
- Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021 - January 12th, 2021
- 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes - January 12th, 2021
- Myriad Genetics Forms Strategic Partnership with Illumina in Oncology - January 12th, 2021
- Alexis RIDEAU appointed CEO of DEINOVE - January 12th, 2021
- Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of... - January 12th, 2021
- Gilead holds 25.54% of Galapagos shares - January 12th, 2021
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - January 12th, 2021
- GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020 - January 12th, 2021
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12th, 2021
- EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues - January 12th, 2021
- Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene - January 12th, 2021
- Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference - January 12th, 2021
- INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium - January 12th, 2021
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- Generation Bio Announces Closing of Public Offering - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Women In Bio Elects Katie Williams, Associate Director of Business Development at Applied BioMath, as 2021 President-Elect - January 8th, 2021
- ExCellThera announces UM171 mechanism of action - January 8th, 2021
Recent Comments